Clinical Impact of Sphingosine-1-Phosphate in Breast Cancer
Breast cancer metastasizes to lymph nodes or other organs, which determine the prognosis of patients. It is difficult to cure the breast cancer patients with distant metastasis due to resistance to drug therapies. Elucidating the underlying mechanisms of breast cancer metastasis and drug resistance...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2017/2076239 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832556931165716480 |
|---|---|
| author | Junko Tsuchida Masayuki Nagahashi Kazuaki Takabe Toshifumi Wakai |
| author_facet | Junko Tsuchida Masayuki Nagahashi Kazuaki Takabe Toshifumi Wakai |
| author_sort | Junko Tsuchida |
| collection | DOAJ |
| description | Breast cancer metastasizes to lymph nodes or other organs, which determine the prognosis of patients. It is difficult to cure the breast cancer patients with distant metastasis due to resistance to drug therapies. Elucidating the underlying mechanisms of breast cancer metastasis and drug resistance is expected to provide new therapeutic targets. Sphingosine-1-phosphate (S1P) is a pleiotropic, bioactive lipid mediator that regulates many cellular functions, including proliferation, migration, survival, angiogenesis/lymphangiogenesis, and immune responses. S1P is formed in cells by sphingosine kinases and released from them, which acts in an autocrine, paracrine, and/or endocrine manner. S1P in extracellular space, such as interstitial fluid, interacts with components in the tumor microenvironment, which may be important for metastasis. Importantly, recent translational research has demonstrated an association between S1P levels in breast cancer patients and clinical outcomes, highlighting the clinical importance of S1P in breast cancer. We suggest that S1P is one of the key molecules to overcome the resistance to the drug therapies, such as hormonal therapy, anti-HER2 therapy, or chemotherapy, all of which are crucial aspects of a breast cancer treatment. |
| format | Article |
| id | doaj-art-fe376b027e2c429f8a1486fb2a92b311 |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-fe376b027e2c429f8a1486fb2a92b3112025-02-03T05:44:07ZengWileyMediators of Inflammation0962-93511466-18612017-01-01201710.1155/2017/20762392076239Clinical Impact of Sphingosine-1-Phosphate in Breast CancerJunko Tsuchida0Masayuki Nagahashi1Kazuaki Takabe2Toshifumi Wakai3Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-dori, Chuo-ku, Niigata City, Niigata 951-8510, JapanDivision of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-dori, Chuo-ku, Niigata City, Niigata 951-8510, JapanBreast Surgery, Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY 14263, USADivision of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-dori, Chuo-ku, Niigata City, Niigata 951-8510, JapanBreast cancer metastasizes to lymph nodes or other organs, which determine the prognosis of patients. It is difficult to cure the breast cancer patients with distant metastasis due to resistance to drug therapies. Elucidating the underlying mechanisms of breast cancer metastasis and drug resistance is expected to provide new therapeutic targets. Sphingosine-1-phosphate (S1P) is a pleiotropic, bioactive lipid mediator that regulates many cellular functions, including proliferation, migration, survival, angiogenesis/lymphangiogenesis, and immune responses. S1P is formed in cells by sphingosine kinases and released from them, which acts in an autocrine, paracrine, and/or endocrine manner. S1P in extracellular space, such as interstitial fluid, interacts with components in the tumor microenvironment, which may be important for metastasis. Importantly, recent translational research has demonstrated an association between S1P levels in breast cancer patients and clinical outcomes, highlighting the clinical importance of S1P in breast cancer. We suggest that S1P is one of the key molecules to overcome the resistance to the drug therapies, such as hormonal therapy, anti-HER2 therapy, or chemotherapy, all of which are crucial aspects of a breast cancer treatment.http://dx.doi.org/10.1155/2017/2076239 |
| spellingShingle | Junko Tsuchida Masayuki Nagahashi Kazuaki Takabe Toshifumi Wakai Clinical Impact of Sphingosine-1-Phosphate in Breast Cancer Mediators of Inflammation |
| title | Clinical Impact of Sphingosine-1-Phosphate in Breast Cancer |
| title_full | Clinical Impact of Sphingosine-1-Phosphate in Breast Cancer |
| title_fullStr | Clinical Impact of Sphingosine-1-Phosphate in Breast Cancer |
| title_full_unstemmed | Clinical Impact of Sphingosine-1-Phosphate in Breast Cancer |
| title_short | Clinical Impact of Sphingosine-1-Phosphate in Breast Cancer |
| title_sort | clinical impact of sphingosine 1 phosphate in breast cancer |
| url | http://dx.doi.org/10.1155/2017/2076239 |
| work_keys_str_mv | AT junkotsuchida clinicalimpactofsphingosine1phosphateinbreastcancer AT masayukinagahashi clinicalimpactofsphingosine1phosphateinbreastcancer AT kazuakitakabe clinicalimpactofsphingosine1phosphateinbreastcancer AT toshifumiwakai clinicalimpactofsphingosine1phosphateinbreastcancer |